Centene Corporation is grappling with a 43.2% decline year-to-date, driven by membership losses in Medicaid and Medicare Advantage along with soaring medical costs. Its adjusted net margin has plummeted to negative 0.2% from 2.3% last year, as the health benefits ratio reached 93% in Q2 2025. Despite rapid growth in its commercial market memberships, the company's heavy debt load of $17.6 billion and a Zacks Rank of #5 (Strong Sell) signal a troubling outlook in the current healthcare landscape.
“The S&P 500 · closed · in the green · on Friday”
“The S&P 500 Health Care Index Sector · declined · about 1.8% · during the week”
“Centene · increased · 9.68% · last week”
“Molina Healthcare · increased · 9.66% · last week”
“McKesson · increased · 8.89% · last week”
“Universal Health Services · increased · 6.46% · last week”
“Cencora · increased · 5.86% · last week”
“Mettler-Toledo International · decreased · 4.83% · last week”
“Regeneron Pharmaceuticals · decreased · 4.75% · last week”
“Baxter International · decreased · 4.52% · last week”
“Incyte · decreased · 4.43% · last week”
“Charles River Laboratories · decreased · 4.40% · last week”
